Response to comment on

DOI QR Code

Response to comment on "New therapeutic agents in diabetic nephropathy"

Kim, Yaeni (Division of Nephrology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
Park, Cheol Whee (Division of Nephrology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea)

Kim Y, Park CW. New therapeutic agents in diabetic nephropathy. Korean J Intern Med 2017;32:11-25. https://doi.org/10.3904/kjim.2016.174
Lindhardt M, Persson F, Currie G, et al. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. BMJ Open 2016;6:e010310. https://doi.org/10.1136/bmjopen-2015-010310
Katayama S, Yamada D, Nakayama M, et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complications 2017;31:758-765. https://doi.org/10.1016/j.jdiacomp.2016.11.021
Sato N, Ajioka M, Yamada T, et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circ J 2016;80:1113-1122. https://doi.org/10.1253/circj.CJ-16-0122
Kolkhof P, Nowack C, Eitner F. Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens 2015;24:417-424. https://doi.org/10.1097/MNH.0000000000000147